Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Clinical trial NCT07261163 · RECRUITING
Trial details
- NCT number
- NCT07261163
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-20
- Primary completion
- 2027-07-31
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.